Comparing Blueprint Medicines (BPMC) and Its Competitors

Blueprint Medicines (NASDAQ: BPMC) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Blueprint Medicines to similar businesses based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, risk and earnings.

Volatility & Risk

Blueprint Medicines has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Blueprint Medicines’ rivals have a beta of 1.57, indicating that their average share price is 57% more volatile than the S&P 500.

Profitability

This table compares Blueprint Medicines and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Blueprint Medicines -437.83% -43.11% -34.38%
Blueprint Medicines Competitors -3,290.32% -529.07% -39.72%

Valuation and Earnings

This table compares Blueprint Medicines and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Blueprint Medicines $27.77 million -$72.49 million -21.35
Blueprint Medicines Competitors $217.29 million -$39.39 million -74.27

Blueprint Medicines’ rivals have higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Blueprint Medicines and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines 0 0 9 0 3.00
Blueprint Medicines Competitors 526 2396 6598 124 2.66

Blueprint Medicines currently has a consensus price target of $70.47, suggesting a potential downside of 3.23%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.24%. Given Blueprint Medicines’ rivals higher possible upside, analysts clearly believe Blueprint Medicines has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

91.4% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 3.4% of Blueprint Medicines shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

What are top analysts saying about Blueprint Medicines Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Blueprint Medicines Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit